Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platforms to potential new drug candidates is therefore very uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; (vi) if Nektar is unable to establish and maintain collaboration partnerships on attractive commercial terms (such as for NKTR-102), our business, results of operations and financial condition could suffer; and (vii) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the SEC on July 28, 2010, the Current Report on Form 8-K filed with the SEC today, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 to be filed with the SEC on or about November 4, 2010.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics(650) 631-4954Susan Noonan/SA Noonan Communications, LLC(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners(650) 575-1509 Michelle Corral/BCC Partners(415) 794-866
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... company developing its Symphony® CGM System as a ... that Robert F. Doman , Executive Chairman ... at "TEN", Noble Financial Capital Markets, Tenth Annual ... make a corporate presentation to prospective corporate partners ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced that it expects revenues for ... $53 million, bringing expected full-year 2013 revenues to ... growth of 87% for 2013 above 2012 reflects ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Perrigo Company (Nasdaq: PRGO ; TASE) today announced ... fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 ... at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo,s ... be available live via webcast to interested parties on the ...
... As previously announced, WebMD Health Corp. (Nasdaq: WBMD ) ... Annual Meetings of Stockholders beginning at 9:30 a.m. Eastern Time on ... of the meetings will be available over the Internet. To listen ... www.wbmd.com (in the Investor Relations section) or at ...
Cached Medicine Technology:WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 2
(Date:4/14/2014)... April 14, 2014 Popular web information on ... to read and doesn,t address the appropriate risks to ... Medical Center gastroenterologists suggests. , In a review of ... education materials for colorectal cancer screening were written beyond ... sites failed to address key risks, as well as ...
(Date:4/14/2014)... FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a ... the destruction of human red blood cells exposed ... of autoimmune hemolytic anemia (AIHA). The article entitled ... prevents complement activation induced by cold agglutinin disease ... Blood earlier this month. TNT003 is ...
(Date:4/14/2014)... Frank Porter Graham Child Development Institute have released ... program to prepare four-year-olds for success in kindergarten. ... Pre-K show significant gains across all areas of ... even greater rate during their participation in NC ... senior scientist Ellen Peisner-Feinberg, who leads the FPG ...
(Date:4/14/2014)... Ohio Heart patients with beliefs about health that ... skip sessions of cardiac rehabilitation, new research suggests. , ... of these beliefs referred to as "irrational health ... was associated with lower adherence to a prescribed cardiac ... Doubting the preventive power of the flu vaccine or ...
(Date:4/14/2014)... high-risk bladder cancer, chemotherapy before or after surgery ... The findings are published early online in ... Cancer Society. , Clinical trials have shown that ... cancer who are given chemotherapy before surgery. There ... also improves survival. To investigate the use of ...
Breaking Medicine News(10 mins):Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 3
... , FERNDALE, Mich. and NEW YORK, Aug. ... today the acquisition of PRESCRIBED solutions [CUSTOMIZED SKINCARE]. Since ... among top dermatologists and plastic surgeons with its innovative, customizable ... product Stop the Clock(TM) Triple Action Anti-aging Day ...
... , SAN FRANCISCO, Aug. 14 While natural ... higher than 50 percent and none have been clinically proven to regulate ... e alth International (NHI), a vertically integrated San ... line has been clinically proven to alleviate symptoms of menopause in ...
... minimize the risk as fall looms, experts say , FRIDAY, ... year have another worry besides homework and lunchroom bullies: swine ... early and vigorously to reduce their risk of contracting the ... is going to strike the school-age child and it,s primarily ...
... , , BELLEVUE, Wash., Aug. ... solutions, today announced the new Edifecs5010(TM) Compliance ... and services for healthcare providers, payers, health plans, ISVs, and clearinghouses ... , , Edifecs, the gold standard for HIPAA ...
... , , KENILWORTH, N.J., Aug. ... announced that the U.S. Food and Drug Administration (FDA) has ... in adults and acute treatment of manic or mixed episodes ... in adults. SAPHRIS can be used as a first-line treatment ...
... , NEW YORK, Aug. 14 MS -- ... by AstraZeneca, found that while most patients with asthma understand ... accordingly. , , "This finding demonstrates ... and the necessary steps people should take to achieve better ...
Cached Medicine News:Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 2Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 3Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2Health News:Get Smart About Swine Flu for Back-to-School 2Health News:Get Smart About Swine Flu for Back-to-School 3Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 2Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 4Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 5Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 6Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 7Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 8Health News:Keeping Asthma Under Control 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: